The pharmacology of monoclonal antibodies: [with 34 tables]
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin [u.a.]
Springer
1994
|
| Schriftenreihe: | Handbook of experimental pharmacology
113 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | XXI, 406 S. Ill., graph. Darst. |
| ISBN: | 354057123X 038757123X |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV009297071 | ||
| 003 | DE-604 | ||
| 005 | 20140403 | ||
| 007 | t | ||
| 008 | 940321s1994 ad|| |||| 00||| eng d | ||
| 016 | 7 | |a 940399351 |2 DE-101 | |
| 020 | |a 354057123X |9 3-540-57123-X | ||
| 020 | |a 038757123X |9 0-387-57123-X | ||
| 035 | |a (OCoLC)29358406 | ||
| 035 | |a (DE-599)BVBBV009297071 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-355 |a DE-12 |a DE-29 |a DE-20 |a DE-11 |a DE-188 |a DE-578 | ||
| 050 | 0 | |a QP905 | |
| 050 | 0 | |a QR186.85 | |
| 082 | 0 | |a 615.1 | |
| 082 | 0 | |a 615/.1 |2 20 | |
| 082 | 0 | |a 615.37 | |
| 082 | 0 | |a 615/.37 |2 20 | |
| 084 | |a XD 3100 |0 (DE-625)152552:12905 |2 rvk | ||
| 084 | |a XI 1701 |0 (DE-625)152977:12907 |2 rvk | ||
| 084 | |a QV 4 |2 nlm | ||
| 084 | |a MED 970f |2 stub | ||
| 084 | |a MED 460f |2 stub | ||
| 245 | 1 | 0 | |a The pharmacology of monoclonal antibodies |b [with 34 tables] |c contributors R. Balint ... Ed. Martin Rosenberg ... |
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 1994 | |
| 300 | |a XXI, 406 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Handbook of experimental pharmacology |v 113 | |
| 500 | |a Literaturangaben | ||
| 650 | 7 | |a Monoclonal Antibodies |2 cabt | |
| 650 | 7 | |a Therapy |2 cabt | |
| 650 | 7 | |a Genetic Engineering |2 cabt | |
| 650 | 7 | |a Pharmacology |2 cabt | |
| 650 | 7 | |a Farmacotherapie |2 gtt | |
| 650 | 7 | |a Monoklonale antistoffen |2 gtt | |
| 650 | 4 | |a Antibodies, Monoclonal |x pharmacology | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 0 | 7 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immunotoxin |0 (DE-588)4209677-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |D s |
| 689 | 0 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Immunotoxin |0 (DE-588)4209677-7 |D s |
| 689 | 1 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Rosenberg, Martin J. |e Sonstige |4 oth | |
| 700 | 1 | |a Balint, Robert Frederick |e Sonstige |4 oth | |
| 830 | 0 | |a Handbook of experimental pharmacology |v 113 |w (DE-604)BV002390716 |9 113 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006186905&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-006186905 | ||
Datensatz im Suchindex
| _version_ | 1804123738477690880 |
|---|---|
| adam_text | THE PHARMACOLOGY OF MONOCLONAL ANTIBODIES CONTRIBUTORS R. BALINT, C.F.
BARBAS, R.D. BLUMENTHAL, P. CARTER, M. CHATTERJEE CHEN, Y.-C. JACK, R.M.
CONRY, K.A. FOON, D.M. GOLDENBERG E. HABER, M. HEIN, A. HIATT, K. JAMES,
K.D. JANDA, K. KARJALAINEN H. KOHLER, J.W. LARRICK, A.F. LOBUGLIO, N.
LONBERG, G.E. MARK E.A. PADLAN, S.H. PINCUS, A. PLUCKTHUN, M.L.
RODRIGUES R.G. RUPP, M.N. SALEH, M.R. SHALABY, R.M. SHARKEY A.
TRAUNECKER EDITORS MARTIN ROSENBERG AND GORDON P. MOORE SPRINGER-VERLAG
BERLIN HEIDELBERG NEW YORK LONDON PARIS TOKYO HONG KONG BARCELONA
BUDAPEST CONTENTS SECTION I: HUMAN MONOCLONAL ANTIBODIES CHAPTER 1 HUMAN
MONOCLONAL ANTIBODY TECHNOLOGY K. JAMES. WITH 2 FIGURES 3 A.
INTRODUCTION 3 I. WHY PRODUCE HUMAN MONOCLONALS? 3 II. CHAPTER AIMS 3
III. APPROACH USED 4 B. GENERAL PRODUCTION STRATEGIES 4 I. INTRODUCTION
4 II. SOURCE OF IMMUNE LYMPHOCYTES 4 1. USUAL SOURCES 4 2. IN VITRO
IMMUNIZATION 7 3. GENERATING IMMUNE LYMPHOCYTES IN SEVERE COMBINED
IMMUNODEFICIENCY MICE 7 III. PROCESSING OF LYMPHOID TISSUES 8 IV.
IMMORTALIZATION STRATEGIES 8 1. INTRODUCTION 8 2. CELL FUSION 9 3.
EPSTEIN-BARR VIRUS FUSION 10 4. COMBINED EPSTEIN-BARR VIRUS
TRANSFORMATION AND CELL FUSION 10 5. NOVEL APPROACHES 11 V. SELECTION,
CLONING AND EXPANSION 11 1. INTRODUCTION 11 2. SELECTION 11 3. CLONING
11 4. EXPANSION 12 5. ADDITIONAL EVALUATION 12 VI. BISPECIFIC AND
TRISPECIFIC ANTIBODIES 13 C. HUMAN MONOCLONAL TARGETS 13 I. ANTIBODY
SPECIFICITIES GENERATED 13 XII CONTENTS II. APPLICATION OF HUMAN
MONOCLONAL ANTIBODY TECHNOLOGY 13 1. INTRODUCTION 13 2. TUMOUR FIELD 14
3. AIDS RESEARCH 15 4. AUTOIMMUNITY 16 5. FUTURE TARGETS 16 D.
LIMITATIONS OF ORTHODOX TECHNOLOGY 16 I. INTRODUCTION 16 II. WHY IS
ANTIBODY SECRETION UNSATISFACTORY? 17 III. IS UNSATISFACTORY SECRETION
RELATED TO CELL SURFACE PHENOTYPE OR CYTOKINE SECRETION? 17 E.
CONCLUSION 18 I. IMPACT AND POTENTIAL OF RECOMBINANT TECHNOLOGY 18 1.
CHIMERIC AND HUMANIZED ANTIBODIES 18 2. REPERTOIRE CLONING 19 3.
COMBINING CELL AND GENE CLONING TECHNOLOGIES 19 REFERENCES 19 CHAPTER 2
RECOMBINANT THERAPEUTIC HUMAN MONOCLONAL ANTIBODIES J.W. LARRICK AND R.
BALINT 23 A. THERAPEUTIC HUMAN MONOCLONAL ANTIBODIES 23 B. RAPID DIRECT
CLONING OF ANTIBODY VARIABLE REGIONS 25 C. GENETICALLY ENGINEERED
CHIMERIC MONOCLONAL ANTIBODIES 30 I. CHIMERIC ANTIBODIES 30 1. SUMMARY
OF WORK WITH THERAPEUTIC CHIMERIC MONOCLONAL ANTIBODIES 31 II.
RECOMBINANT CONJUGATES AND FUSION PROTEINS 32 1. IMMUNOTOXINS 32 2. A
RECOMBINANT MONOCLONAL ANTIBODY LINKED TO TISSUE-TYPE PLASMINOGEN
ACTIVATOR 32 3. T CELL RECEPTOR CONJUGATES 33 4. GROWTH FACTOR
CONJUGATES 33 5. OTHER FUSION PROTEINS 34 6. ANTIBODY-ENZYME CONJUGATES
FOR CANCER 34 D. RESHAPED OR COMPOSITE ANTIBODIES 35 E. IMMORTALIZATION
OF THE IMMUNOGLOBULIN REPERTOIRE USING RDNA TECHNOLOGY 37 F.
RECOMBINATORIAL ANTIBODY LIBRARIES 38 G. PHAGE ANTIBODY LIBRARIES:
WHOLLY SYNTHETIC MONOCLONAL ANTIBODIES 39 REFERENCES 41 CONTENTS XIII
CHAPTER 3 TRANSGENIC APPROACHES TO HUMAN MONOCLONAL ANTIBODIES N.
LONBERG. WITH 11 FIGURES 49 A. INTRODUCTION 49 B. COMPETING TECHNOLOGIES
FOR THE GENERATION OF THERAPEUTIC ANTIBODIES 50 C. ORIGINS OF ANTIBODY
DIVERSITY 52 I. FUNCTIONAL REQUIREMENTS FOR A HUMAN IMMUNOGLOBULIN
TRANSGENE 52 II. STRUCTURE OF THE HUMAN IMMUNOGLOBULIN LOCI 55 1. THE
HUMAN X LIGHT CHAIN LOCUS 57 2. THE HUMAN K LIGHT CHAIN LOCUS 57 3. THE
HUMAN HEAVY CHAIN LOCUS 57 D. TRANSGENIC TECHNOLOGY 58 I. PRONUCLEAR
MICROINJECTION 59 II. EMBRYONIC STEM CELLS 59 III. TRANSGENE CONSTRUCTS
60 1. BACTERIOPHAGE CLONING VECTORS 60 2. PLASMID CLONING VECTORS 61 3.
YEAST ARTIFICIAL CHROMOSOME VECTORS 62 E. IMMUNOGLOBULIN TRANSGENICS .
64 I. HIGH LEVEL AND CELL TYPE SPECIFIC EXPRESSION 64 1. CW-ACTING
REGULATORY SEQUENCES 64 2. TRANSGENE EXPRESSION 65 3. HUMAN TRANSGENE
CONSTRUCTS 65 II. REARRANGEMENT 66 1. TARGET SEQUENCES 66 2.
IMMUNOGLOBULIN GENE REARRANGEMENTS IN TRANSGENIC MICE 68 3. LIGHT CHAIN
JUNCTIONS 68 4. HEAVY CHAIN JUNCTIONS 70 5. REPERCUSSIONS OF MOUSE B
CELL ENVIRONMENT ON HUMAN VDJ JOINTS 71 III. ALLELIC EXCLUSION 74 1.
BACKGROUND 74 2. INDUCTION OF ALLELIC EXCLUSION BY REARRANGED TRANSGENES
75 3. RESPONSE TO ALLELIC EXCLUSION BY UNREARRANGED TRANSGENES 76 4.
ALTERNATIVES TO DIRECT FEEDBACK ALLELIC EXCLUSION 77 IV. PRIMARY
REPERTOIRE 77 V. INTRACELLULAR SIGNALING 78 1. BACKGROUND 78 2. B CELL
RECEPTOR COMPLEX 79 XIV CONTENTS 3. PRE-B CELL COMPLEX 81 VI. CLASS
SWITCHING 82 1. BACKGROUND 82 2. CLASS SWITCHING IN TRANSGENIC MICE 82
3. IMPORTANCE OF CLASS SWITCHING FOR A HUMAN ANTIBODY MOUSE 83 VII.
SUBSTRATE FOR SOMATIC MUTATION 85 VIII. DOMINATION OF THE IMMUNE
RESPONSE 86 1. ANTIBODY DEPLETION 87 2. ANTI-SENSE TRANSGENES 87 3. GENE
TARGETING 88 F. PERSPECTIVE 89 REFERENCES 90 SECTION II: GENETICALLY
ENGINEERED MONOCLONAL ANTIBODIES CHAPTER 4 HUMANIZATION OF MONOCLONAL
ANTIBODIES G.E. MARK AND E.A. PADLAN. WITH 10 FIGURES 105 A.
INTRODUCTION 105 B. STRUCTURE OF ANTIBODIES 105 I. GENERAL 105 II. THE
ANTIBODY COMBINING SITE 107 III. COMPLEMENTARITY DETERMINING REGIONS 107
IV. INFLUENCE OF FRAMEWORK RESIDUES ON COMBINING SITE STRUCTURE 108 C.
STRATEGIES FOR THE HUMANIZATION OF ANTIBODIES 109 I. TRANSPLANTING A
NONHUMAN COMBINING SITE ONTO A HUMAN FRAMEWORK 109 II. RECOMBINANT
METHODOLOGY OF COMPLEMENTARITY DETERMINING REGION TRANSFER 116 1.
POLYMERASE CHAIN REACTION-MEDIATED COMPLEMENTARITY DETERMINING REGION
TRANSFER 116 2. HUMANIZATION OF THE MURINE MONOCLONAL ANTIBODY IB4 119
3. ANTIBODY RESHAPING 122 III. REPLACING SURFACE RESIDUES TO HUMANIZE
(VENEERING) .... 122 D. IMMUNOGENICITY OF HUMANIZED ANTIBODIES 130 E.
CONCLUSION 131 REFERENCES 132 CONTENTS XV CHAPTER 5 APPLICATIONS FOR
ESCHERICHIA CO//-DERIVED HUMANIZED FAB FRAGMENTS: EFFICIENT
CONSTRUCTION OF BISPECIFIC ANTIBODIES P. CARTER, M.L. RODRIGUES, AND
M.R. SHALABY. WITH 3 FIGURES 135 A. INTRODUCTION 135 B. CHOICE OF
ANTIGEN SPECIFICITIES FOR BISPECIFIC F(AB ) 2 137 C. EXPRESSION OF
HUMANIZED FAB FRAGMENTS IN E. COLI 137 D. RECOVERY OF FAB -SH FRAGMENTS
138 E. CONSTRUCTION OF BISPECIFIC F(AB ) 2 139 F. USES OF E.
COLI-DERIVED FAB FRAGMENTS 141 G. CONCLUSIONS 143 REFERENCES 143
SECTION III: MAB CONJUGATES AND FUSIONS CHAPTER 6 IMMUNOTOXINS S.H.
PINCUS. WITH 2 FIGURES 149 A. INTRODUCTION 149 B. CONSIDERATIONS IN
IMMUNOTOXIN DEVELOPMENT 150 I. IN VITRO TESTING TO IDENTIFY EFFECTIVE
ANTIBODIES 150 II. IMMUNOTOXIN DESIGN 151 C. THE TOXIC MOIETY 153 I.
RICIN 154 II. PSEUDOMONAS EXOTOXIN A 154 III. DIPHTHERIA TOXIN 157 IV.
DRUG CONJUGATES 157 V. NOVEL APPROACHES 158 D. CELL BIOLOGY OF
IMMUNOTOXIN ACTION 159 E. PHARMACOLOGY OF IMMUNOTOXIN ADMINISTRATION 160
I. PHARMACOKINETICS 160 II. PHARMACOLOGIC ENHANCEMENT OF IMMUNOTOXIN
ACTION 161 III. IMMUNOGENICITY 162 F. CLINICAL APPLICATIONS 163 I.
CANCER 163 II. IMMUNOSUPPRESSION 165 1. TRANSPLANTATION 165 2.
AUTOIMMUNE DISEASE 166 III. INFECTIOUS DISEASES 167 XVI CONTENTS IV.
DISORDERED CELLULAR GROWTH 168 G. CONCLUSIONS 168 REFERENCES 170 CHAPTER
7 ANTIBODY-ENZYME FUSION PROTEINS AND BISPECIFIC ANTIBODIES E. HABER.
WITH 2 FIGURES 179 A. INTRODUCTION 179 B. ANTIBODY-ENZYME FUSION
PROTEINS 179 I. DEVELOPMENT OF THE CONCEPT OF A BIFUNCTIONAL PROTEIN
.... 179 II. CHEMICALLY CROSS-LINKED CONJUGATES AS MODELS FOR FUSION
PROTEINS 181 1. CROSS-LINKED ANTIBODY-PLASMINOGEN ACTIVATOR CONJUGATES
181 2. METHODS FOR SYNTHESIZING AND PURIFYING CROSS-LINKED CONJUGATES
182 III. FUSION PROTEIN CONSTRUCTION 184 1. CLONING THE REARRANGED
IMMUNOGLOBULIN GENE 184 2. CONSTRUCTING THE EXPRESSION VECTOR 184 3.
SELECTING LOSS VARIANT CELL LINES 185 4. TRANSFECTING THE EXPRESSION
PLASMID 185 5. PURIFYING AND ANALYZING PROTEIN 185 6. RECOMBINANT
PROTEIN EXPRESSION LEVELS 185 IV. STRUCTURAL AND FUNCTIONAL PROPERTIES
OF SPECIFIC FUSION PROTEINS- 186 1. ANTIBODY-PLASMINOGEN ACTIVATOR
FUSION PROTEINS 186 2. A MODEL MINIMAL SIZE FUSION PROTEIN 188 3. FV AND
SINGLE CHAIN FV 188 4. MINIMAL FV-CONTAINING FUSION PROTEIN 189 5.
PRODRUG ACTIVATION 190 C. BISPECIFIC ANTIBODIES 192 I. DEVELOPMENT OF
THE CONCEPT OF A BISPECIFIC ANTIBODY 192 II. CHEMICALLY CROSS-LINKED
BISPECIFIC ANTIBODIES AS MODELS 192 III. CELL FUSION IN THE PRODUCTION
OF BISPECIFIC ANTIBODIES 192 IV. FUNCTIONAL PROPERTIES OF BISPECIFIC
ANTIBODIES 193 D. CONCLUSION 193 REFERENCES 194 CONTENTS XVII CHAPTER 8
THREE GENERATIONS OF RECOMBINANT CD4 MOLECULES AS ANTI-HIV REAGENTS A.
TRAUNECKER AND K. KARJALAINEN. WITH 2 FIGURES 199 A. INTRODUCTION 199 B.
GENERAL ASPECTS OF HIV INFECTION 199 C. CHARACTERISTICS OF DIFFERENT
FORMS OF SCD4 200 I. FIRST GENERATION: TRUNCATED FORMS OF SCD4 200 II.
SECOND GENERATION: CD4-IMMUNOGLOBULINS 200 III. THIRD GENERATION:
CD4-FVCD3 JANUSINS 201 D. MOLECULAR DESIGNS AND STRATEGIES TO PRODUCE
RECOMBINANT CD4 MOLECULES 202 I. PRODUCTION OF SCD4 MOLECULES 202 II.
CD4-CK MOLECULES 202 III. MULTIVALENT SCD4 MOLECULES: CD4
IMMUNOGLOBULINS 203 IV. BISPECIFIC REAGENTS: CD4-FVCD3 JANUSINS 204 E.
CONCLUDING REMARKS 205 REFERENCES 205 SECTION IV: COMBINATORIAL
LIBRARIES CHAPTER 9 CHEMICAL AND BIOLOGICAL APPROACHES TO CATALYTIC
ANTIBODIES K.D. JANDA AND Y.-C. JACK CHEN. WITH 18 FIGURES 209 A.
INTRODUCTION 209 B. BACKGROUND 211 I. BASES OF ENZYMATIC CATALYSIS 211
C. HAPTEN DESIGN STRATEGIES FOR CATALYTIC ANTIBODIES 215 I. TRANSITION
STATE STABILIZATION 215 II. ENTROPIC EFFECTS 222 III. CHARGE
COMPLEMENTARITY 223 IV. SOLVENT EFFECTS 225 D. CATALYTIC ANTIBODIES IN
ORGANIC SOLVENTS 227 E. BIOLOGICAL ASPECTS 229 I. HYBRIDOMA TECHNIQUES
229 II. AUXOTROPHIC SELECTION 230 III. EXPRESSION METHODS 233 F.
PROSPECTS 236 REFERENCES 237 XVIII CONTENTS CHAPTER 10 THE COMBINATORIAL
APPROACH TO HUMAN ANTIBODIES C.F. BARBAS III. WITH 10 FIGURES 243 A.
INTRODUCTION 243 B. THE COMBINATORIAL APPROACH 243 C. FROM SCREENING TO
SELECTION 245 D. FEATURES OF THE COMBINATORIAL APPROACH 248 E. HUMAN
ANTIVIRAL ANTIBODIES 251 I. INTRODUCTION 251 II. ANTIBODIES TO HIV-1 252
1. RATIONALE 252 2. SOURCE OF RNA 253 3. CHARACTERIZATION OF ANTIBODIES
253 III. ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS 256 IV. ANTIBODIES TO
HEPATITIS B VIRUS 258 F. ALTERNATIVES TO THE USE OF SEROPOSITIVE HUMANS
258 I. NAIVE LIBRARIES 258 II. SYNTHETIC AND SEMISYNTHETIC ANTIBODIES
260 III. HUMAN ANTIBODIES FROM SEVERE COMBINED IMMUNODEFICIENCY MICE 260
IV. ANTIBODIES FROM CHIMPANZEES 261 G. PRODUCTION OF WHOLE ANTIBODIES
AND GENE RESCUE FROM CELL LINES 261 H. THE FUTURE OF ANTIBODIES 262
REFERENCES 263 SECTION V: EXPRESSION OF MABS/MAB FRAGMENTS CHAPTER 11
ANTIBODIES FROM ESCHERICHIA COLI A. PLUCKTHUN. WITH 11 FIGURES 269 A.
INTRODUCTION 269 B. EXPRESSION OF FUNCTIONAL ANTIBODY FRAGMENTS IN E.
COLI BY SECRETION 270 I. GENERAL OVERVIEW 270 II. RELATION OF FUNCTIONAL
SECRETION TO PHAGE LIBRARIES 272 III. DESCRIPTION OF THE SECRETION
PROCESS 274 IV. THE ROLE OF PERIPLASMIC PROTEIN FOLDING 276 V. CATALYSIS
OF PERIPLASMIC PROTEIN FOLDING 277 1. DISULFIDE BOND FORMATION 277 2.
PROLINE CIS-TRANS ISOMERIZATION 280 CONTENTS XIX VI. DESIGN OF SECRETION
VECTORS 281 VII. FERMENTATION 286 VIII. CLONING ANTIBODIES BY POLYMERASE
CHAIN REACTION 287 IX. PURIFICATION 288 C. EXPRESSION OF ANTIBODY
FRAGMENTS AS INCLUSION BODIES 289 D. ANTIBODY FRAGMENTS 292 I. FV
FRAGMENTS 293 II. SINGLE CHAIN FV FRAGMENTS 294 III. DISULFIDE-LINKED FV
FRAGMENTS 296 IV. MINI-ANTIBODIES 297 1. MINI-ANTIBODIES BASED ON
COILED-COIL HELICES 300 2. MINI-ANTIBODIES BASED ON FOUR-HELIX BUNDLES
303 E. CONCLUSIONS 304 REFERENCES 304 CHAPTER 12 STRUCTURE, FUNCTION AND
USES OF ANTIBODIES FROM TRANSGENIC PLANTS AND ANIMALS A. HIATT AND M.
HEIN 317 A. INTRODUCTION 317 B. TRANSGENIC ANTIBODIES FROM MICE 318 C.
POTENTIAL USES OF ANTIBODY EXPRESSION IN TRANSGENIC ANIMALS ... 318 I.
INVESTIGATION OF IMMUNE SYSTEM REGULATION 318 II. HUMAN MONOCLONAL
ANTIBODIES IN ANIMALS 319 III. PATHOGEN PROTECTION IN AGRICULTURAL
ANIMALS 319 D. TRANSGENIC ANTIBODIES FROM PLANTS 320 E. STRUCTURE AND
FUNCTION OF ANTIBODIES FROM PLANTS 322 I. GLYCOSYLATION OF ANTIBODIES
PRODUCED IN PLANTS 323 II. ANTIBODY PROCESSING AND ASSEMBLY 323 III.
MUTAGENESIS TO REMOVE N-LINKED GLYCOSYLATION 324 IV. DELETION OF HEAVY
CHAIN CONSTANT REGIONS 325 F. POTENTIAL USES OF ANTIBODIES EXPRESSED IN
TRANSGENIC PLANTS .... 325 I. SCALE AND ECONOMICS OF PLANTIBODY
PRODUCTION 325 II. POTENTIAL MEDICAL USES OF PLANT PRODUCED ANTIBODIES
326 III. PATHOGEN PROTECTION IN AGRICULTURAL PLANTS 327 REFERENCES 328
CHAPTER 13 SOME ASPECTS OF MONOCLONAL ANTIBODY PRODUCTION R.G. RUPP.
WITH 4 FIGURES 331 REFERENCES 344 XX CONTENTS SECTION VI: MEDICAL
APPLICATIONS CHAPTER 14 PROSPECTS FOR CANCER IMAGING AND THERAPY WITH
RADIOIMMUNOCONJUGATES D.M. GOLDENBERG, R.D. BLUMENTHAL, AND R.M.
SHARKEY. WITH 2 FIGURES : 347 A. INTRODUCTION 347 B. NATURE AND
PHARMACOLOGY OF RADIOIMMUNOCONJUGATES 347 C. RADIOIMMUNOCONJUGATES IN
DETECTION VS THERAPY 350 D. NATURE AND PROBLEMS OF RADIOIMMUNODETECTION
351 E. NATURE AND PROBLEMS OF RADIOIMMUNOTHERAPY 353 F. CURRENT CLINICAL
STATUS OF RADIOIMMUNOTHERAPY 357 G. EXPERIMENTAL STUDIES OF ADJUVANT
RADIOIMMUNOTHERAPY 359 H. CONCLUSIONS AND FUTURE PROSPECTS 362
REFERENCES 362 CHAPTER 15 CLINICAL EXPERIENCE WITH MURINE, HUMAN AND
GENETICALLY ENGINEERED MONOCLONAL ANTIBODIES M.N. SALEH, R.M. CONRY, AND
F. LOBUGLIO 369 A. INTRODUCTION 369 B. DIFFICULTIES ENCOUNTERED WITH
MURINE MONOCLONAL REAGENTS 370 I. IMMUNOGENICITY OF MURINE ANTIBODIES
370 II. PHARMACOKINETICS OF MURINE ANTIBODIES 371 III. CLINICAL EFFICACY
OF MURINE ANTIBODIES 372 1. IN CANCER 372 2. IN NONMALIGNANT DISORDERS
373 IV. TOXICITY ASSOCIATED WITH MURINE ANTIBODIES 374 C. HUMAN
MONOCLONAL ANTIBODY TRIALS 374 D. CHIMERIC ANTIBODY TRIALS 376 E.
CDR-GRAFTED HUMANIZED MONOCLONAL ANTIBODY TRIALS 378 F. FUTURE PROSPECTS
379 REFERENCES 380 CONTENTS XXI CHAPTER 16 ANTI-IDIOTYPIC MONOCLONAL
ANTIBODIES: NOVEL APPROACH TO IMMUNOTHERAPY M. CHATTERJEE, K.A. FOON,
AND H. KOHLER. WITH 1 FIGURE 387 A. INTRODUCTION 387 B. ADVANTAGES OF
ANTI-IDIOTYPIC ANTIBODIES OVER CONVENTIONAL VACCINES 388 C. ACQUIRED
IMMUNE DEFICIENCY SYNDROME 389 D. SOLID TUMORS AND CUTANEOUS T CELL
LYMPHOMA 391 E. B CELL LYMPHOMAS AND LEUKEMIAS 394 F. CONCLUSION 396
REFERENCES 397 SUBJECT INDEX 403
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV009297071 |
| callnumber-first | Q - Science |
| callnumber-label | QP905 |
| callnumber-raw | QP905 QR186.85 |
| callnumber-search | QP905 QR186.85 |
| callnumber-sort | QP 3905 |
| callnumber-subject | QP - Physiology |
| classification_rvk | XD 3100 XI 1701 |
| classification_tum | MED 970f MED 460f |
| ctrlnum | (OCoLC)29358406 (DE-599)BVBBV009297071 |
| dewey-full | 615.1 615/.1 615.37 615/.37 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1 615/.1 615.37 615/.37 |
| dewey-search | 615.1 615/.1 615.37 615/.37 |
| dewey-sort | 3615.1 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02510nam a2200673 cb4500</leader><controlfield tag="001">BV009297071</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20140403 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">940321s1994 ad|| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">940399351</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">354057123X</subfield><subfield code="9">3-540-57123-X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">038757123X</subfield><subfield code="9">0-387-57123-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)29358406</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV009297071</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP905</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR186.85</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.1</subfield><subfield code="2">20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.37</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.37</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XD 3100</subfield><subfield code="0">(DE-625)152552:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1701</subfield><subfield code="0">(DE-625)152977:12907</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 4</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 970f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 460f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The pharmacology of monoclonal antibodies</subfield><subfield code="b">[with 34 tables]</subfield><subfield code="c">contributors R. Balint ... Ed. Martin Rosenberg ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, 406 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">113</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Monoclonal Antibodies</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapy</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Genetic Engineering</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacology</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Farmacotherapie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Monoklonale antistoffen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibodies, Monoclonal</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monoclonal antibodies</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immunotoxin</subfield><subfield code="0">(DE-588)4209677-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Immunotoxin</subfield><subfield code="0">(DE-588)4209677-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosenberg, Martin J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balint, Robert Frederick</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">113</subfield><subfield code="w">(DE-604)BV002390716</subfield><subfield code="9">113</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006186905&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006186905</subfield></datafield></record></collection> |
| id | DE-604.BV009297071 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:34:32Z |
| institution | BVB |
| isbn | 354057123X 038757123X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006186905 |
| oclc_num | 29358406 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-12 DE-29 DE-20 DE-11 DE-188 DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-12 DE-29 DE-20 DE-11 DE-188 DE-578 |
| physical | XXI, 406 S. Ill., graph. Darst. |
| publishDate | 1994 |
| publishDateSearch | 1994 |
| publishDateSort | 1994 |
| publisher | Springer |
| record_format | marc |
| series | Handbook of experimental pharmacology |
| series2 | Handbook of experimental pharmacology |
| spelling | The pharmacology of monoclonal antibodies [with 34 tables] contributors R. Balint ... Ed. Martin Rosenberg ... Berlin [u.a.] Springer 1994 XXI, 406 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Handbook of experimental pharmacology 113 Literaturangaben Monoclonal Antibodies cabt Therapy cabt Genetic Engineering cabt Pharmacology cabt Farmacotherapie gtt Monoklonale antistoffen gtt Antibodies, Monoclonal pharmacology Monoclonal antibodies Monoklonaler Antikörper (DE-588)4040094-3 gnd rswk-swf Immunotoxin (DE-588)4209677-7 gnd rswk-swf Pharmakologie (DE-588)4045687-0 gnd rswk-swf Monoklonaler Antikörper (DE-588)4040094-3 s Pharmakologie (DE-588)4045687-0 s DE-604 Immunotoxin (DE-588)4209677-7 s Rosenberg, Martin J. Sonstige oth Balint, Robert Frederick Sonstige oth Handbook of experimental pharmacology 113 (DE-604)BV002390716 113 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006186905&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | The pharmacology of monoclonal antibodies [with 34 tables] Handbook of experimental pharmacology Monoclonal Antibodies cabt Therapy cabt Genetic Engineering cabt Pharmacology cabt Farmacotherapie gtt Monoklonale antistoffen gtt Antibodies, Monoclonal pharmacology Monoclonal antibodies Monoklonaler Antikörper (DE-588)4040094-3 gnd Immunotoxin (DE-588)4209677-7 gnd Pharmakologie (DE-588)4045687-0 gnd |
| subject_GND | (DE-588)4040094-3 (DE-588)4209677-7 (DE-588)4045687-0 |
| title | The pharmacology of monoclonal antibodies [with 34 tables] |
| title_auth | The pharmacology of monoclonal antibodies [with 34 tables] |
| title_exact_search | The pharmacology of monoclonal antibodies [with 34 tables] |
| title_full | The pharmacology of monoclonal antibodies [with 34 tables] contributors R. Balint ... Ed. Martin Rosenberg ... |
| title_fullStr | The pharmacology of monoclonal antibodies [with 34 tables] contributors R. Balint ... Ed. Martin Rosenberg ... |
| title_full_unstemmed | The pharmacology of monoclonal antibodies [with 34 tables] contributors R. Balint ... Ed. Martin Rosenberg ... |
| title_short | The pharmacology of monoclonal antibodies |
| title_sort | the pharmacology of monoclonal antibodies with 34 tables |
| title_sub | [with 34 tables] |
| topic | Monoclonal Antibodies cabt Therapy cabt Genetic Engineering cabt Pharmacology cabt Farmacotherapie gtt Monoklonale antistoffen gtt Antibodies, Monoclonal pharmacology Monoclonal antibodies Monoklonaler Antikörper (DE-588)4040094-3 gnd Immunotoxin (DE-588)4209677-7 gnd Pharmakologie (DE-588)4045687-0 gnd |
| topic_facet | Monoclonal Antibodies Therapy Genetic Engineering Pharmacology Farmacotherapie Monoklonale antistoffen Antibodies, Monoclonal pharmacology Monoclonal antibodies Monoklonaler Antikörper Immunotoxin Pharmakologie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006186905&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002390716 |
| work_keys_str_mv | AT rosenbergmartinj thepharmacologyofmonoclonalantibodieswith34tables AT balintrobertfrederick thepharmacologyofmonoclonalantibodieswith34tables |